Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared on LinkedIn:
“Hot off the press and pleased to share with the – our new publication in JAMA Oncology.
Title: Beyond Tumor Size, Toward Meaningful Patient Outcomes—Resisting RECIST
Authors: Chadi Nabhan, Vivek Subbiah
Viewpoint with world famous book author Chadi Nabhan.
RECIST based tumor measurements still matters for standardization, but it should no longer be the primary arbiter of response. The field has evolved.
Our response criteria should too –> Yes! Resist RECIST.”
You can also read:
Vivek Subbiah Showcases Real-Time Precision Oncology at the WIN Symposium
